M. Cobo

OA13.05 NADIM Study: Updated Clinical Research and Outcomes

N. Viñolas, B. Massuti, M. Provencio, 2019, Journal of Thoracic Oncology.

PL03.12 Progression Free Survival and Overall Survival in NADIM II Study

J. Bosch-Barrera, M. Provencio, C. Camps, 2022, Journal of Thoracic Oncology.

MA06.03 Pre-treatment ctDNA Levels Significantly Predicts of OS and PFS in NADIM II Trial

J. Bosch-Barrera, M. Provencio, C. Camps, 2022, Journal of Thoracic Oncology.

P2.04-10 Biomarkers of Pathological Response on Neo-Adjuvant Chemo-Immunotherapy Treatment for Resectable Stage IIIA NSCLC Patients

N. Viñolas, B. Massuti, M. Provencio, 2019, Journal of Thoracic Oncology.

P76.03 Efficacy and Safety of Capmatinib Plus Nivolumab in Pretreated Patients with EGFR Wild-Type Non–Small Cell Lung Cancer

Ying Cheng, E. Felip, J. Wolf, 2021 .

OA20.02 Pre-Treatment Levels of ctDNA for Long-Term Survival Prediction in Stage IIIA NSCLC Treated With Neoadjuvant Chemo-Immunotherapy

N. Viñolas, B. Massuti, M. Provencio, 2021, Journal of Thoracic Oncology.

OA20.01 Long Term Survival in Operable Stage Iiia Nsclc Patients Treated With Neoadjuvant Nivolumab Plus Chemotherapy - Nadim Study

N. Viñolas, B. Massuti, M. Provencio, 2021, Journal of Thoracic Oncology.

1269P EMPOWER-lung 4: Phase II, randomized, open-label high dose or standard dose cemiplimab alone/plus ipilimumab in the second-line treatment of advanced non-small cell lung cancer (NSCLC)

C. Chiu, I. Lowy, S. Lee, 2020 .

Glucagonoma with two pancreatic masses and pulmonary metastases as debut of MEN-1

D. Bautista, M. Cobo, J. Alcalde, 2007, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.

Two biomarker-directed randomized trials in European and Chinese patients with nonsmall-cell lung cancer: the BRCA1-RAP80 Expression Customization (BREC) studies.

A Vergnenegre, X. Chen, X. Qian, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

LBA2 Updated analysis and patient-reported outcomes (PROs) from CITYSCAPE: A randomised, double-blind, phase II study of the anti-TIGIT antibody tiragolumab + atezolizumab (TA) versus placebo + atezolizumab (PA) as first-line treatment for PD-L1+ NSCLC

T. Hoang, M. Huang, D. Rodríguez-Abreu, 2021, Annals of Oncology.

Erlotinib in patients with advanced squamous cell carcinoma of the lung.

L. Paz-Ares, A. Gúrpide, C. Pallarés, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.